![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 for tinnitus, emergent symptoms lasting longer than 4 weeks since onset.
Lead Product(s): Pimozide
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: JW-600
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Biology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022